B+
Bull case
20%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-05-27 · RankAlpha Sentiment Codex
INDP
Indaptus TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-05-27 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.25
Analysis reference price unavailable
Analysis 2026-05-27 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-27
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Cautious monitoring stance. The packet is filing-driven, not news-driven, and contains no recent trusted-news or social signal. Primary evidence points to a very tight cash runway, ongoing burn, and a program reset, while post-print price reaction and analyst revision data are unavailable in the packet. That keeps conviction low and the setup dependent on financing or a credible funded development path rather than operating momentum.
RankAlpha Sentiment Codex - 2026-05-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15eventQ1 results showed lower loss but did not solve cash burnHigh impact
The May 15 press release/8-K framed Q1 2026 results as a lower net loss year over year, but operating cash use remained elevated, so the improvement in the P&L did not remove the funding overhang [#8-K-2026-05-15].
2026-06-30catalystRunway pressure and dilution risk stay immediateHigh impact
The May 15 10-Q/8-K package says cash and cash equivalents were about $1.5 million at March 31, 2026 and management expected funding only through Q2 2026, leaving fresh capital or strategic financing as the key near-term variable [#10-Q-2026-05-15][#8-K-2026-05-15].
2026-12-31catalystAny Decoy20 restart or partnership would be the main upside leverHigh impact
Management said it discontinued further enrollment in the Combination Study and is reevaluating Decoy20 and development priorities, so a durable re-rating likely requires a funded restart, partnership, or other concrete strategic path [#8-K-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-27 • Updated nightlySource: Internal modelMethodology